VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer | 2 Minute Medicine
GEMSTONE Educational Module Last Update: January 9, ppt download
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives | Journal of Clinical Oncology
Platinum sensitivity is classified as refractory, resistant, or... | Download Scientific Diagram
Medicina | Free Full-Text | Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? | Gynecologic Oncology Research and Practice | Full Text
Evolution of platinum resistance in high-grade serous ovarian cancer - The Lancet Oncology
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) | Journal for ImmunoTherapy of Cancer | Full Text
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study - The Lancet Oncology
Platinum sensitivity is classified as refractory, resistant, or... | Download Scientific Diagram
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Anlotinib combined with TQB2450 in patients with platinum-resistant or - refractory ovarian cancer: A multi-center, single-arm, phase 1b trial - ScienceDirect
Platinum resistance - Dr Vineet Govinda Gupta Oncology - World-class Cancer Care In Delhi NCR
Molecular Mechanisms of Platinum Resistance in Ovarian Cancer | IntechOpen
Searching for a Biomarker for Platinum-Refractory Advanced Epithelial Ovarian Cancer
A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer | SpringerLink
Clinical benefit (A) Duration on treatment of 28 enrolled patients.... | Download Scientific Diagram
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer | BioSpace
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) | Nature Communications
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment in: Endocrine-Related Cancer Volume 25 Issue 5 (2018)
